BCL6 and breast carcinoma: The effect of BCL6 inhibition on cell viability was observed in both TNBC and ER+ paclitaxel‐treated cells, suggesting that inhibition of BCL6 could be incorporated as a potential strategy across breast cancer subtypes and not just in a subset of patients.